Bahrain authorizes COVAXIN for emergency use

  • article

Manama, Nov. 11 The Kingdom of Bahrain’s National Health Regulatory Authority (NHRA) today approved the emergency use of the COVID-19 vaccination, COVAXIN, produced by Indian multinational biotechnology company, “Bharat Biotech”. 

COVAXIN, an inactivated vaccine, was recently approved by the World Health Organization, and will be available in Bahrain for those aged 18 years and above. 

The decision follows the careful evaluation of data provided by the manufacturer, Bharath Biotech India, carried out by the NHRA's Clinical Trials Committee and the Ministry of Health's Immunization Committee. 

More than 26,000 people participated in the vaccine’s clinical trials, which established that the two-dose regimen vaccine is 77.8% effective against COVID-19, and 93.4% effective against severe cases of COVID-19. Safety data indicated a low incidence of adverse effects.